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ABSTRACT 
There is a lack of biochemical markers for non-invasive and objective assessment of symptomatic 
osteoarthritis (OA). Aggrecanase activity has been shown to be associated with joint deterioration and 
symptomatic disease through the degradation of extracellular matrix proteins, such as type III collagen. 
Our study aimed to identify and develop a novel biomarker by measuring an aggrecanase-mediated type 
III collagen neoepitope, and correlate levels of this biomarker with OA joint pain. Mass spectrometric 
analysis of purified type III collagen, degraded by the aggrecanase A Disintigrin and Metalloproteinase 
with Thrombospondin motif (ADAMTS), revealed a fragment generated by ADAMTS-1, -4 and -8. A 
monoclonal antibody was raised against the neoepitope of this fragment (COL3-ADAMTS) and a 
competitive ELISA was developed and tested; using serum samples from a cross-sectional cohort of 
patients with different degrees of knee OA (n=261). The COL3/ADAMTS ELISA was technically robust and 
specific for the ADAMTS-1, -4 and -8 generated neoepitope. COL3/ADAMTS was released form cytokine 
stimulated synovial cultures, indicating a biologic link between the marker and synovium. In OA patients, 
serum COL3/ADAMTS was independently associated with pain scores (rho=-0.13-0.17, p<0.05). This 
association was associated significantly with the presence of radiographic OA. Together, these data 
indicate that COL3/ADAMTS could be a marker of early osteoarthritis and the underlining pathology. 
Keywords: Biochemical markers, type III collagen, pain, OA, ADAMTS, protease-cleaved neoepitope. 
Keywords: Type III collagen, ADAMTS, Knee osteoarthritis, neoepitope, 
biochemical marker 
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ABBRIVIATIONS 
ADAMTS A Disintigrin and Metalloproteinase with Thrombospondin motif 
COL3 type III collagen 
ECM extracellular matrix 
OA osteoarthritis 
VAS visual analog score 
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HIGHLIGHTS 
 That a technical robust ELISA, COL3/ADAMTS, was developed which show good sensitivity for 
measurement in human serum samples 
 COL3/ADAMTS was released from human osteoarthritis synovial membranes cultured is the 
presence of proinflammatory cytokines, indicating a link to synovial pathology and inflammation 
 When the marker was measured in serum of 261 subjects with or without knee pain, we found 
that it was significantly and inversely associated with radiographic knee osteoarthritis. 
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1 INTRODUCTION 
Osteoarthritis (OA) is characterized by a gradual deterioration of articular joint cartilage, along with 
remodeling of subchondral bone and synovial inflammation. The process is partly driven by an 
upregulation of aggrecanases and matrix metalloproteinases (MMPs), which degrade and remodel the 
extracellular matrix (ECM) of joint tissues  [1]. The ECM mainly consists of collagens, proteoglycans and 
glycoproteins, all of which play important and unique functions in maintaining the physicochemical 
structure of tissue [1-3]. ECM remodelling is a normal process in which formation and degradation of 
healthy tissue is balanced, however an imbalance exists in disease, which manifests itself in various 
pathologies. Degradation of the cartilage by the aggrecanase, A Disintigrin and Metalloproteinase with 
Thrombospondin motif (ADAMTS),  is well described [2][3]; whereas the role of ADAMTS in the turnover 
of the fibrous synovial tissue, is less so. Increased ADAMTS activity has been found in the synovial fluid 
of OA patients[4], thus the action of these enzymes may not only be restricted to the cartilage. 
The fibril-forming type III collagen is mainly associated with type I collagen, and together they provide 
the structural framework of most connective tissues, including the synovial membrane which surrounds 
synovial joints [5]. Type III collagen contributes to synovial tissue elasticity, a property that is uniquely 
connected to this type of collagen [6]. Type III collagen is also found in healthy cartilage and is thought 
to stabilize the type II collagen framework [7].  
The pathogenesis of OA involves an inflammatory response, and the activation of chondrocytes, 
fibroblasts and leukocytes partly mediates tissue turnover by the secretion of  MMPs and ADAMTSs [3]. 
Type III collagen  is upregulated in response to pro-inflammatory cytokines such as  tumor necrosis 
factor α (TNF-α) and interleukin 1 (IL-1β)[8] which results in thickening of the synovial membrane. In 
addition, type III collagen has been found to be elevated in osteoarthritic cartilage [9]. Pro-inflammatory 
cytokines also upregulate the release of ADAMTS from articular cartilage leading to degradation of both 
cartilage and synovial membrane ECM [10,11]. Collagen fragments are released into circulation and can 
potentially be assessed as markers of joint degradation in synovial fluid, serum and urine. Such protein 
fragments, referred to as neoepitopes or protein fingerprints [12,13], have proven to be more accurate 
than their intact protein of origin, in detecting and quantifying certain pathophysiological processes [14]. 
For example, fragments of type II collagen, generated by MMPs, have been shown to be markers of 
cartilage degradation and joint deterioration  in OA and rheumatoid arthritis (RA) [15].  
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The aim of the present study was to develop a novel ELISA specific for an ADAMTS generated fragment 
of type III collagen. In addition, we determined whether ADAMTS mediated degradation of type III 
collagen may be useful for monitoring joint type III collagen turnover in OA, along with its relationship 
with symptomatic disease, particularly pain and function.  
2 MATERIALS AND METHODS 
2.1 Patient samples  
Serum COL3/ADAMTS levels were measured in a total of 261 subjects belonging to the cross-sectional 
C4P-003 study [16]. Subjects had different degrees of primary knee OA defined by different degrees of 
knee pain (maximal pain during the last 24 hours rated on a visual analog scale [VAS]) (VAS 0-100), and 
different degrees of radiological knee OA (Kellgren and Lawrence grade (KLG)). Radiographic knee OA 
(RKOA) was defined as having a KLG of 2 [17]. Only subjects which had a complete set of matching 
serum, X-rays and questionnaires available were included in the current investigation (261 out of 282 
subjects with available serum samples)[18]. Subjects were segregated into four groups based on their 
VAS pain score: no pain: VAS <10 (n = 52), mild pain: VAS 10 to 39 (n = 81), moderate pain: VAS 40 to 69 
(n = 67) and severe pain: VAS 70 to 100 (n = 61). Age, BMI, and disease duration (if any), as well as 
WOMAC [19] and Lequesne [20] scores were collected (table 1). All subjects were Caucasian and 
abstained from analgesic medication for at least 72 hours [16]. The study was approved by the Danish 
ethical committee (VEK; The Ethical committee of North Jutland no.: N-20100094).  
2.2 Reagents 
All reagents used for experiments were standard high-quality chemicals from companies such as Merck 
(Whitehouse Station, NJ, USA) and Sigma Aldrich (St. Louis, MO, USA). The synthetic peptides used for 
monoclonal antibody (mAb) production and assay development were purchased from the Chinese 
Peptide Company (Beijing, China). 
2.3 In vitro cleavage 
Purified type III collagen from human placenta (Abcam, Cambridge, UK) was cleaved with pro-ADAMTS-
1,-4, and -8  and MMP-9 (Calbiochem, Merck, Whitehouse Station, NJ, USA). 50 g pro-ADAMTS’ or 
MMP-9 was activated with 20 L 1 mM 4-aminophenylmercuric acetate (APMA) in dimethyl sulfoxide 
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(DMSO) and incubated at 37°C for 2 hours. 1 mg/mL type III collagen, diluted in 0.5 M acetic acid, was 
dialyzed into MMP buffer (100 mM Tris-HCl, 100 mM NaCl, 10 mM CaCl2, 2 mM Zn acetate, pH 8.0) for 
two days at 4oC,  and proteins below 10 kDa removed by filter centrifugation (Microcon Ultracel YM-10, 
cat. no. 42407, Millipore, Billerica, MA, USA). Each digest was performed separately by mixing 100 µg 
type III collagen with 1 µg of enzyme (ADAM-TS -1, -4, -8 or MMP-9) in MMP buffer (n=4). As a control, 
100 g of type III collagen was mixed with MMP buffer only. All digests were incubated for 24 h at 37°C 
and terminated using 5 mM EDTA. Cleavage with cathapsin K and S was done in 25 mM NA2HPO4, 150 
mM NaCl, 2 mM EDTA, 2 mM DTT, pH 6.5 at 37°C and the digest was stopped after 24 h 1 µM cysteine 
protease inhibitor E64 (cat.no.219377, Calbiochem, Merck, Whitehouse Station, NJ, USA). Collagen 
cleavage was verified by SDS-PAGE separation, and visualized using SilverXpress® Silver Staining Kit (cat. 
no. LC6100, Invitrogen, Carlsbad, Ca, USA) according to the manufacturer’s instructions.  
2.4 Peptide identification 
Peptide fragments of in vitro cleaved type III collagen were identified using liquid chromatography 
coupled to electrospray ionization (ESI) tandem mass spectrometry (LC-MS/MS). Type III collagen/ 
ADAMTS digests were ultra-filtrated to remove proteins above 10kDa, the pH adjusted to 2.0 using 
formic acid and 4 L of sample was analyzed by LC-MS/MS. LC was performed on a nanoACQUITY UPLC 
BEH C18 column (Waters, Milford, MA, USA) using a formic acid/acetonitrile gradient. MS and MS/MS 
were performed on a Synapt High Definition Mass Spectrometry quadruple time of flight MS (QUAD-
TOF; Waters, Milford, MA, USA), with an acquisition range of 350-1600 m/z in MS and 50-2000 m/z, in 
MS/MS. The software “ProteinLynx Global SERVER (PLGS)” (Waters, Milford, MA, USA) was used to 
analyze spectra and generate peak lists. To identify peptides, MS and MS/MS data was searched against 
a type III collagen (FASTA) protein database using the Mascot 2.2 (Matrix Science, Boston, MA, USA) 
software with ESI-QUAD-TOF settings with carbamidomethyl (C), oxidation of methionine (M), oxidation 
of lysine (K) and oxidation of proline (P) as variable modifications. Only sequences identified with a 
significant Mascot score were regarded further. 
2.5 Selection of peptide for immunizations 
The first six amino acids of collagen fragment free ends, identified by MS, were regarded as a 
neoepitope generated by each ADAMTS in question. All protease-generated sequences were analyzed 
for homology and distance to other cleavage sites, then blasted for homology using the NPS@: network 
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protein sequence analysis [42]. Six type III collagen sequences, identified in fragments generated by 
ADAMTS cleavage, were selected for immunizations. 
2.6 Immunization procedure 
Six 4-6 week old Balb/C mice were immunized subcutaneously in the abdomen with 200 μL emulsified 
antigen (50 μg per immunization) per immunization program, using Freund’s incomplete adjuvant. 
Immunizations using the following immunogen provided a neoepitope specific antibody: GAPGFRGPAG-
CGG-KLH (American Peptide, Hongkong, China). Immunizations were performed at two-week intervals 
until stable titer levels were obtained. At each bleeding, the serum titer was investigated and the mouse 
with the highest titer was selected for fusion. The selected mice were boosted intravenously with 50 μg 
immunogen in 100 μL 0.9% sodium chloride solution three days before isolation of the spleen for cell 
fusion. Only one immunogen resulted in satisfactory immune response; the remaining programs were 
terminated. 
2.7 Fusion and antibody screening 
The fusion procedure has been described elsewhere [43]. Briefly, mouse spleen cells were fused with 
SP2/0 myeloma fusion partner cells. The hybridoma cells were cloned using a semi-solid medium 
method and transferred into 96-well microtiter plates for further growth. Here, standard limited dilution 
was used to promote monoclonal growth. Supernatants were screened using an indirect ELISA, while the 
biotinylated peptide GAPGFRGPAG-K-Biotin (American Peptide, Hongkong, China) was used as a catcher 
peptide on streptavidin-coated microtitre plates. 
2.8 Characterization of clones 
Native reactivity and peptide binding of mAbs was evaluated in a preliminary competitive ELISA.  mAbs 
in hybridoma supernatant competed with samples of human, rat or mouse serum and plasma, for 
biotinylated peptide (5 ng/mL), bound to a streptavidin coated microtitre plate. Clones were also tested 
against the free synthetic peptide (GAPGFRGPAG), a non-sense synthetic peptide, and a synthetic 
peptide elongated with one amino acid at the free N-terminal end (RGAPGFRGPAG). Isotyping of the 
mAbs was performed using the Clonotyping System-HRP kit, cat.5300-05 (Southern Biotech, Birmingham, 
AL, USA). The selected clones were purified using Protein G columns according to manufacturer’s 
instructions (GE Healthcare Life Science, Little Chalfont, Buckinghamshire, UK). 
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2.9 COL3/ADAMTS ELISA protocol 
We labeled selected mAbs (5D9) with horseradish peroxidase (HRP) using the Lightning link HRP labeling 
kit according to the instructions of the manufacturer (Innovabioscience, Babraham, Cambridge, UK). A 
96-well streptavidin plate was coated with biotinylated synthetic peptide GAPGFRGPAG-K-Biotin 
dissolved in assay buffer (25 mM PBS, 1% BSA, 0.1% Tween-20, pH 7.4 adjusted at 4oC) and incubated 30 
minutes at 20°C. 20 µL of free 10 amino acid peptide calibrator (GAPGFRGPAG) or sample were added to 
appropriate wells, followed by 100 µL of HRP conjugated mAb and incubated 1 hour at 20°C. Finally, 100 
µL tetramethylbenzinidine (TMB) (Kem-En-Tec cat.438OH) was added and the plate was incubated for 
15 minutes at 20oC in the dark. All the above incubation steps included shaking at 300 rpm. After each 
incubation step, the plate was washed five times in washing buffer (20 mM Tris, 50 mM NaCl, pH 7.2). 
The TMB reaction was stopped by adding 100 µL of stopping solution (1% HCl) and measured at 450 nm 
with 650 nm as the reference. A calibration curve was plotted using a 4-parametric mathematical fit 
model. 
2.10 Technical evaluation 
From 2-fold dilutions of quality control (QC) samples consisting of serum and plasma samples, linearity 
was calculated as a percentage of recovery of the 100% sample. The lower limit of detection (LDL) was 
determined from 21 zero samples (i.e. buffer) and calculated as the mean plus three standard 
deviations. The inter- and intra-assay variation was determined by 10 independent runs of six QC 
samples. The developed COL3/ADAMTS ELISA was evaluated using protease digests described under “In 
vitro cleavage”. 20 L from a sample diluted 1:20 was used for the assay.  
2.11 Explant cultures 
Human synovial tissue and cartilage used for ex vivo cultures was collected from OA patients undergoing 
total knee replacement at Gentofte Hospital, Denmark. All patients gave written informed consent 
(Danish science ethical committee, amendment no. 53713, approval no. H-D-2007-0084). Synovial tissue 
and cartilage were stored separately until receipt. Human synovial membrane samples were cleaned of 
visible fat, and cut into explants (hSMEx) of 30 ± 5 mg. Human cartilage was punched into 5 mm explants 
(HEX) with a biopsy punch (Miltex, MTP-33-35). hSMEx were co-cultured with HEX at a one-to-one ratio, 
or cultured separately as mono-cultures. All explants were cultured in Dulbecco’s Modified Eagle 
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Medium supplemented with F12, GlutaMAX™ and 1% penicillin and streptomycin (Sigma-Aldrich, 
Denmark) in 48 well plates for 14 days; without treatment (W/O) or with TNFα [20ng/mL] and 
oncostatin M (OSM) [10 ng/mL] (O+T). Conditioned media was removed and fresh treatment added 
every 2-3 days. Undiluted conditioned media was used for the measurement of COL3/ADAMTS. Synovial 
tissue from two patients and cartilage from four patients was used. Synovial tissue and cartilage from 
the same patient were co-cultured. However due to insufficient amount of cartilage, the synovial tissue 
was also co-cultured with cartilage from another patient. A total of six replica were included in the 
experiment.  
2.12 Statistical analysis 
Results are shown as mean with 95% confidence intervals, SEM or SD. Differences between mean values 
were compared by either Mann-Whitney’s t-test for two-tailed observations or ANCOVA adjusting for 
covariates (age, gender, BMI and smoker status (yes/no)). The P values were Bonferroni corrected. 
Associations between the marker COL3/ADAMTS and clinical pain scores were tested weight least 
squares multiple regression (AutoWeight 1/SD^2) adjusting for the covariates. Odds ratio (OR) and area 
under the curve (AUC) were calculated by logistic regression including the covariates. P values less than 
0.05 were considered significant. Statistical analyses were performed Medcalc® (version 17.2) and plots 
were done by using GraphPad Prism (version 7).  
3 RESULTS 
3.1 Identification of ADAMTS generated type III collagen fragments  
A large number of type III collagen fragments with statistically significant Mascot score (p<0.05) were 
identified after in vitro cleaved by ADAMTS -1, 4, or -8. The protease-generated neoepitopes were 
tested for homology between human and rat. The sequence 486’GAPGFRGPAG’495 (C3A) in the alpha 
1 chain of type III collagen,  generated by ADAMTS -1, -4 and -8 (), was selected for immunizations 
since it is 100% homologous to human and rat type III collagen.  
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3.2 COL3/ADAMTS ELISA development, characterization and technical 
performance 
An IgG1 mAb was produced, selected and used for the development of a solid-phase competitive ELISA, 
COL3/ADAMTS. The ELISA signal was completely inhibited by 250 ng/mL of specific neoepitope peptide, 
whereas an elongated peptide inhibited the signal by less than <10% at the same concentration (Fig. 
1A). A nonsense peptide did not inhibit the signal (Fig. 1A). Type III collagen cleaved by different ECM 
associated proteases was tested in the COL3/ADAMTS ELISA to verify the sensitivity towards the target 
epitope. It was observed that ADAMTS -1, -4, and –8 were able to generate the COL3/ADAMTS fragment 
(Fig. 1B), with ADAMTS-4 generating by far the most. There was little or no reactivity towards intact 
human type III collagen or fragments generated by the cathepsins and MMPs tested. These findings 
were consistent in two repeated cleaved batches.  
The assay specifications are summarized in Table 2. Briefly, the assay range was between 2 and 60 ng/ml 
and linearity was within 100 ± 15% for human serum down to an 8-fold dilution (table 2). The inter- and 
intra-assay variations, using human serum and urine QC samples, were both below 10% (table 2).  
 
3.3 Biological target validation 
COL3/ADAMTS was measured in the conditioned media of human osteoarthritic cartilage explants 
(HEXs), synovial membrane explants (hSMEx), and co-cultured explants, over the course of 14 days using 
the COL3/ADAMTS ELISA. COL3/ADAMTS was released from co-cultures, and hSMExs alone, with O+T 
stimulation in a time-dependent fashion, with peak release at day 3 (Fig. 2A). Patient associated 
variance was observed, especially with hSMExs, however release of COL3/ADAMTS was 3-fold higher 
from co-cultured explants after 14 days of 0+T stimulation, compared to unstimulated controls (w/o),  
(p<0.05, Fig. 2B) . 
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3.4 Association between serum COL3/ADAMTS and patient reported pain in 
OA 
The average concentration of COL3/ADAMTS in serum collected from 261 subjects with or without knee 
pain was 21.8 [19.4 to 24.0] ng/ml. Serum COL3/ADAMTS levels were weakly, but significantly, inversely 
associated with pain; determined by VAS (r=-0.15, p<0.05), WOMAC (r=-0.17, p<0.01) and Lequesne (r=-
0.13, p<0.05) assessment, following adjustment for age, BMI and gender (Table 3). There was no 
association between COL3/ADAMTS levels and WOMAC function or stiffness. There was no linear 
correlation between KL grade and COL3/ADAMTS (pANOVA>0.1, data not shown). 
Subjects were separated into four sub-categories based on their VAS pain level, followed by separation 
into those with or without radiographic knee OA (RKOA) (Table 4). There was a significant difference in 
serum levels of COL3/ADAMTS between subjects with no pain, and subjects with mild (p=0.0076) or 
moderate pain (p=0.0019), when RKOA was not considered. Within the RKOA group, COL3/ADAMTS was 
significantly elevated in patients with mild pain (p=0.0086) but there was no difference between non-
RKOA and RKOA patients; thus COL3/ADAMTS levels were not associated with radiographic knee OA, but 
rather with pain status.  
Next, the performance of COL3/ADAMTS was compared to other markers of ECM degradation and joint 
pathology, which have previously been published [18][21]. COL3/ADAMTS could significantly predict 
who would had symptomatic knee OA versus those without (Table 5), with an odds ratio of 0.56 
demonstrating a significant inverse relationship (p= 0.0003). Another marker of type III collagen 
degradation, C3M, which is derived from increased metalloproteinase activity, also inversely correlated 
with symptomatic RKOA and performed better than COL3-ADAMTS; AUC of 0.78 vs 0.72 (Table 5). An 
ADAMTS derived fragment, AGNx1, a metabolite of aggrecan, positively correlated with symptomatic 
RKOA but performed worse than COL3-ADAMTS; 0.65 vs. 0.72. COL3/ADAMTS performed better than 
age and BMI alone (Table 5). 
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4 DISCUSSION 
In this work, we present the identification and development of a novel ELISA-based marker, which 
measures human type III collagen cleavage derived from the activity of ADAMTS. The work showed that 
a sensitive monoclonal antibody was produced, which specifically recognized the collagen type III 
neoepitope, COL3/ADAMTS, and not an elongated or nonsense peptide. The assay was technically 
robust and sufficiently sensitive to detect COL3/ADAMTS in patient serum. We also found that the 
neoepitope was released from human OA synovial membrane when culture in the presence of 
proinflammatory cytokines, indicating that the marker was indeed associated with joint tissue turnover 
and could be relevant as a marker for joint health. 
4.1 The association between COL3/ADAMTS and OA pain 
We tested the ELISA in a cross-sectional cohort, which included 261 subjects with varying degree of 
symptomatic and radiographic OA. We found that serum levels of COL3/ADAMTS significantly and 
inversely correlated with patient pain score (r≈ -0.15). Moreover, that this association was found to be 
related to symptomatic radiographic OA rather than knee pain alone (non-radiographic OA). The 
correlation was weak (r<0.2) which indicates that COL3/ADAMTS is not a strong surrogate marker of 
pain severity. However, it may provide insight to the underlining pathogenesis of ECM remodeling in OA 
and its association with development of pain, which is a key diagnostic feature in OA [22]. Lastly, we 
compared COL3/ADAMTS with other synovial or cartilage markers of either type III collagen (C3M [23]) 
or aggrecanase activity (AGNx1 [24]). We found that low level of COL3/ADAMTS was predictive of 
symptomatic radiographic OA with an odds ratio of 1.8 (1/0.56, p=0.0003, table 5). This was slightly 
better than high level of AGNx1 which had an odds ratio of 1.8, but borderline significant (p=0.066), but 
not as significant as low C3M, which predicted with an odds ratio of 2.5 (1/0.40, p<0.0001). 
Pain in OA is considered multimodal and this weak correlation may indicate that type III collagen 
degradation reflects only part of the underlining mechanism observed in knee pain. Interestingly, the 
correlation was independent of radiographic disease severity, which further supports the idea that 
radiographic OA and pain in OA are not strictly associated [22]. Our results point to the possibility that 
changes in the turnover, both elevated and decreased, of joint connective tissue is associated with 
increased structural severity of OA, which cannot be described by pain or demographics alone. We 
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speculate that COL3/ADAMTS is a potential biomarker for the identification of patients with minimal 
symptomatic knee OA, but with early and potentially progressing OA. 
The pain intensity reported by OA patients seems to be only weakly correlated with radiological score, 
suggesting factors other than cartilage destruction and bony changes are important in OA pain [25]. 
Recent studies have investigated specific groups of patients with OA, characterized by high pain 
intensities but low radiological severity, and these patients seems to be highly sensitive to pain [16,26]. 
Further, low radiological severity before total knee replacement (TKR) has been linked to low 
functionality after surgery and recently, low radiological scores in combination with pain sensitivity 
profiles were found associated with less pain relief following TKR [27]. The current study found 
COL3/ADAMTS to be associated with pain but not radiological scores, which further supports that 
radiological OA, might be less important compared with clinical pain.    
4.2 COL3/ADAMTS and its association with joint biology 
The synovial membrane is remodeled during the pathogenesis of OA, driven by pro-inflammatory 
cytokines; and by fragments known as DAMPs (damage associated molecular patterns) which are 
released from cartilage into the joint cavity upon trauma, and stimulate toll-like receptors which 
mediate further inflammation [28]. As synovial fibroblasts are activated, they proliferate and start 
secreting ECM proteins such as type III collagen. The synovial membrane thickens and become 
vascularized. OA pain is derived from many tissue components, but synovial vascularization and 
innervation are believed to be major contributors [21,29]. Increased expression and turnover of type III 
collagen, with associated release of COL3/ADAMTS from a thickening synovial membrane, may precede 
the onset of mild to moderate pain, when the tissue becomes innervated. Indeed, OA patients with no 
pain had higher levels of serum COL3/ADAMTS compared to those with mild to moderate pain. In 
addition, hSMEx COL3/ADAMTS release peaked with inflammatory stimulation early in the explant 
model at day 3, and decreased to W/O control levels by day 14. Further indicating that COL3/ADAMTS is 
a marker, which may flag the transition between asymptomatic OA and early progressive symptomatic 
OA.  
ADAMTS expression has been shown to be elevated in synoviocytes and chondrocytes of OA patients 
[30,31], and plays a central role in the remodeling of joint connective tissues. Several markers and 
fragments of aggrecan resulting from ADAMTS activity have been described. Fragments containing the 
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sequences ARGS and NITEGE (e.g. measured by the AGNx1 ELISA) have been extensively investigated, 
and biomarkers measuring these neoepitopes have been developed [32,33]. Previously, ADAMTS 
activity was associated only with degradation and deterioration of the joint; however, recent data 
suggest that ADAMTS’ play a vital role in overall tissue turnover. Elevated ADAMTS expression may 
therefore reflect an ongoing, potentially uncontrolled, repair process in response to inflammation and 
injury; and may explain the inverse relationship between COL3/ADAMTS and pain observed in this study. 
4.3 The perspective 
At present there no DMOAD available for OA, however drug are being developed which are believe to 
change joint metabolism. One of these treatments are targeting ADAMTS [34], which have traditionally 
been monitored by biomarkers reflecting cartilage degradation through the release of the neo-epitopes 
ARGS or TEGE from aggrecan [35]. COL3/ADAMTS could be used as a pharmacodynamics marker 
measuring the effect of anti-ADAMTS’ on other tissues than cartilage. 
4.4 Limitations. 
There are several limitations in this study. Firstly, patients with systemic diseases other than 
musculoskeletal disease were not excluded from the study and results were not adjusted for NSAID use; 
both of which could influence serum biomarker levels. Secondly, the clinical study investigated a cross-
sectional cohort, which focused on pain parameters alone, thus cannot provide insight in to the 
prognostic value of the biomarker.  
5 CONCLUSION 
In conclusion, the COL3/ADAMTS ELISA was technically robust and specific for the selected ADAMTS-1, -
4-, -8 generated neoepitope. There was an inverse correlation between COL3/ADAMTS and pain scores, 
which was mainly associated with radiographic OA. These data may indicate that COL3/ADAMTS is a 
marker of early osteoarthritis. Such a biomarker could be used to characterize patients with early and 
mildly progressed disease, and may shed light on which degenerative components contribute to pain 
perception; since there is a disconnect between the degree of joint degeneration and joint pain. 
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Table 1. The C4P-003 study overview 
  1 (No pain) 
VAS pain <10 
mm 
 2 (mild pain) 
VAS pain 10-40 
mm 
 3 (moderate 
pain) 
VAS pain 40-70 
mm 
 4 (severe pain) 
VAS pain 70-100 
mm 
N 52   81   67   61  
No. of females (%) 23 (44)   46 (57)   35 (52)   34 (56)  
 Mean SD  Mean SD  Mean SD  Mean SD 
Age (years) 67.5 4.8  62.8 8.3  64.7 7.6  63.0 8.1 
BMI 27.2 4.0  27.5 3.8  27.9 3.3  29.5 4.9 
Disease duration 
(years) 
6.9 4.9  6.4 5.8  8.1 12.9  9.9 1.2 
VAS pain score 
(mm) 
1.1 2.3  26.2 9.3  54.3 8.1  78.7 7.0 
Lequesne pain score 0.8 1.5  4.3 1.6  5.0 1.5  5.8 1.8 
WOMAC_PAIN 1.0 2.0  6.6 2.8  8.1 2.5  9.4 3.1 
WOMAC function 2.3 4.1  14.8 9.1  22.9 10.6  28.0 10.5 
WOMAC stiffness 0.6 1.1  3.0 1.5  3.9 1.3  4.4 1.6 
KLG, worst score 1.5 0.7  1.9 0.8  2.3 1.1  2.2 0.9 
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Table 2: COL3/ADAMTS ELISA technical performance. A: Measurement range. B: Linearity (percentage 
dilution recovery) of the COL3/ADAMTS ELISA using human serum samples from healthy donors (n=3). 
C: Inter- and intra-assay variation of the COL3/ADAMTS ELISA using human serum and urine QC samples; 
n=6 with 10 independent runs of each QC sample. 
 
Technical performance of the COL3/ADAMTS ELISA 
A: Measurement range IC50, ng/mL Slope  Quantification 
range, ng/mL 
 13.7 [12.7 – 14.9] 0.99 [0.90 – 1.07] 2 - 60 
       
B: Linearity Conc., 
ng/mL 
% 
recovery 
Conc., 
ng/mL 
% 
recovery 
Conc., 
ng/mL 
% 
recovery 
Undiluted human serum sample 27.4 100.0 37.2 100.0 47.3 100.0 
Dilution 1 in 2 14.0 102.4 17.9 96.3 24.9 105.3 
Dilution 1 in 4 7.3 106.8 8.4 90.6 13.1 110.4 
Dilution 1 in 8 3.6 105.5 4.5 96.4 6.0 101.6 
Dilution 1 in 16 2.0 118.6 2.6 112.1 3.7 124.3 
Average recovery, % 99.1 106.6 108.3 
    
C: Assay Variability    
Precision  ng/mL Intra-assay 
variability % 
Inter-assay variability 
% 
Sample 1 31.6 5.5 7.5 
Sample 2 50.3 3.6 3.1 
Sample 3 60.1 5.7 3.0 
Sample 4 69.2 7.0 5.1 
Sample 5 64.3 3.9 5.6 
Sample 6 80.6 6.0 5.9 
Mean  5.3 5.0 
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Table 3. Correlation between COL3/ADAMTS and clinical pain and function measures.  
  COL3-ADAMTS COL3/ADAMTS adjusted for age, gender, BMI 
and smoker status 
 R partial P value R partial P value Significant 
covariates 
VAS PAIN -0.14 0.020 -0.15 0.018 BMI 
WOMAC PAIN -0.16 0.010 -0.17 0.0065 BMI 
Lequesne Pain -0.17 0.0070 -0.13 0.035 BMI, Age, 
Gender 
WOMAC function -0.10 0.099 -0.11 0.066 BMI 
WOMAC stiffness -0.08 Ns - - BMI, gender 
 
Table 4. Levels of serum COL3/ADAMTS in patients with different knee OA pain and radiographic 
phenotypes. The data was corrected for age, gender, BMI and smoker status. 
 
1 (No pain) 
VAS pain <10 mm 
2 (mild pain) 
VAS pain 10-40 mm 
3 (moderate pain) 
VAS pain 40-70 mm 
4 (severe pain) 
VAS pain 70-100 mm 
  N Mean 95% CI N Mean 95% CI P N Mean 95% CI  N Mean 95% CI  
All 52 31.1 
25.9 to 
36.3 
81 19.2 
14.4 to 
24.0 
0.0076 67 17.0 
11.5 to 
22.6 
0.0019 61 24.9 
17.7 to 
32.1 
Ns 
NON 
RKOA 
25 30.7 
23.2 to 
38.2 
21 20.7 
12.3 to 
29.0 
Ns 14 13.6 
3.7 to 
23.5 
Ns 8 29.4 
15.9 to 
42.9 
Ns 
RKOA 27 31.5 
24.4 to 
38.7 
60 17.7 
12.9 to 
22.4 
0.0086 53 20.5 
15.4 to 
25.5 
0.080 53 20.4 
15.3 to 
25.6 
0.097 
 
Table 5. Asymptomatic RKOA vs. symptomatic RKOA. The comparisons were done on Z-transformed 
marker levels. 
 The marker The model 
 OR 95% CI P value AUC 95% CI P value Covariate 
COL3-ADAMTS 0.56 0.41 to 0.77 0.0003 0.72 0.66 to 0.71 <0.0001 Age 
C3M 0.40 0.87 to 0.97 <0.0001 0.78 0.72 to 0.83 <0.0001 Age, BMI 
AGNx1 1.84 0.96 to 3.53 0.066 0.65 0.59 to 0.71 0.024 Age 
Age 0.92 0.88 to 0.97 0.0010 0.67 0.61 to 0.73 0.0003 - 
BMI 1.08 0.99 to 1.16 0.093 0.59 0.53 to 0.65 0.083 - 
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Figure 1. Characterization of the COL3/ADAMTS mAb; specificity of type III collagen neoepitope 
recognition. A) COL3/ADAMTS ELISA standard curve and epitope specificity test. Four-parameter 
interpolated curve using the specific peptide, as well as test of the elongated and a nonsense peptide. B) 
COL3/ADAMTS ELISA assessment of in vitro cleaved type III collagen by common proteases of the ECM. 
Each bar contains four replicates and are shown as mean with SEM bars. 
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Figure 2. Biological target validation using the COL3/ADAMTS ELISA. A) Time-depended release of 
COL3/ADAMTS from synovial membrane (hSMEx) or cartilage explants (HEX) alone or in co-cultures (CC) 
in the presence or absence of the pro-inflammatory cytokines oncostatin M and TNF alpha (O+T). Tissue 
from four different patients was used with six replica per condition. B) Accumulated release of 
COL3/ADAMTS from the explant cultures after 14 days. Error bars are SEM. * indicates statistical 
significance (p<0.05).   
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